CapecitabineTC (docetaxel /cyclophosphamide)EverymonthLoperamideprophylaxisRadiationtherapy10yearsTamoxifenTaxanesOlaparibTDM-1(Ado-trastuzumabemtansine)1yearPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)Pertuzumab2yearsAromataseinhibitorsAbemaciclibAnthracyclinesExemestaneTNBCPembrolizumabVenlafaxineLVEFmonitoringIntermediate(11-25)ChemoendocrinetherapyCapecitabineTC (docetaxel /cyclophosphamide)EverymonthLoperamideprophylaxisRadiationtherapy10yearsTamoxifenTaxanesOlaparibTDM-1(Ado-trastuzumabemtansine)1yearPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)Pertuzumab2yearsAromataseinhibitorsAbemaciclibAnthracyclinesExemestaneTNBCPembrolizumabVenlafaxineLVEFmonitoringIntermediate(11-25)Chemoendocrinetherapy

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Capecitabine
  2. TC (docetaxel / cyclophosphamide)
  3. Every month
  4. Loperamide prophylaxis
  5. Radiation therapy
  6. 10 years
  7. Tamoxifen
  8. Taxanes
  9. Olaparib
  10. TDM-1 (Ado-trastuzumab emtansine)
  11. 1 year
  12. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  13. Pertuzumab
  14. 2 years
  15. Aromatase inhibitors
  16. Abemaciclib
  17. Anthracyclines
  18. Exemestane
  19. TNBC
  20. Pembrolizumab
  21. Venlafaxine
  22. LVEF monitoring
  23. Intermediate (11-25)
  24. Chemoendocrine therapy